Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia

Cancer

Volumn 113, Issue 9, 2008, Pages 2504-2511

  Roboz, Gail J ^a   Ritchie, Ellen K ^a   Curcio, Tania ^a   Provenzano, Juliette ^a   Carlin, Rebecca ^a   Samuel, Michael ^a   Wittenberg, Beth ^a   Mazumdar, Madhu ^a   Christos, Paul J ^a   Mathew, Susan ^a   Allen Bard, Sandra ^a   Feldman, Eric J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acute myeloid leukemia; Arsenic trioxide; Cytarabine; Elderly

Indexed keywords

ANTIANEMIC AGENT; ARSENIC TRIOXIDE; ASCORBIC ACID; AZACITIDINE; CYTARABINE; HYDROXYUREA;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACTEREMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER MORTALITY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOGENETICS; DIARRHEA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ARRHYTHMIA; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LOW DRUG DOSE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NAUSEA; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RASH; REMISSION; SIDE EFFECT; SUBDURAL HEMATOMA; TORSADE DES POINTES; TREATMENT OUTCOME; TREATMENT RESPONSE; VAGINA BLEEDING; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CYTARABINE; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; OXIDES; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE;

EID: 55649106819     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23855     Document Type: Article

References (26)

1. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-3485.
2. Roboz GJ. Treatment of acute myeloid leukemia in older patients. Expert Rev Anticancer Ther. 2007;7:285-295.
3. Menzin J, Lang K, Earle CC, et al. The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med. 2002;162:1597-1603.
4. Degos L, Castaigne S, Tilly H, et al. Treatment of leukemia with low-dose ara-C: a study of 160 cases. Semin Oncol. 1985;12:196-199.
5. Cheson BD, Jasperse DM, Simon R, et al. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol. 1986;4:1857-1864.
6. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114-1124.
7. Schiller GJ, Slack J, Hainsworth JD, et al. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol. 2006;24:2456-2464.
8. Vey N, Bosly A, Guerci A, et al. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol. 2006;24:2465-2471.
9. Parmar S, Rundhaugen LM, Boehlke L, et al. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. Leuk Res. 2004;28:909-919.
10. Douer D, Watkins K, Louie R, et al. Treatment of non-APL acute myelogenous leukemia with intravenous arsenic trioxide plus ascorbic acid [ASH Annual Meeting Abstracts]. Blood. 2006;108. Abstract 1959.
11. 3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. Br J Haematol. 2002;116:555-563.
12. Rojewski MT, Korper S, Schrezenmeier H. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. Leuk Lymphoma. 2004;45:2387-2401.
13. Roboz GJ, Dias S, Lam G, et al. Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood. 2000;96:1525-1530.
14. Miller WH Jr, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62:3893-3903.
15. Douer D, Tallman MS. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol. 2005;23:2396-2410.
16. Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
17. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994;331:896-903.
18. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995;332:1671-1677.
19. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood. 1995;86:457-462.
20. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1998;91:3607-3615.
21. Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy - the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol. 1998;16:872-881.
22. Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1311.
23. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002;100:3869-3876.
24. Buchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and 1 course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003;21:4496-4504.
25. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of 3 induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103:479-485.
26. Burnett AK, Mohite U. Treatment of older patients with acute myeloid leukemia - new agents. Semin Hematol. 2006;43:96-106.